Key clinical point: Sequential treatment with abaloparatide followed by alendronate improves bone mineral density (BMD) in women aged 80 years or more with osteoporosis at high risk for fracture.

Major finding: At 43 months, abaloparatide plus alendronate group vs placebo plus alendronate group had a significantly higher mean percent change in BMD at the lumbar spine (17.2% vs. 8.6%; P less than .0001), total hip (5.3% vs. 3.0%; P = .024), and femoral neck (4.6% vs. 3.1%; P = .044).

Study details: Post hoc analysis of the open-label extension of the ACTIVE study (ACTIVExtend) involving 56 women aged 80 years or more with osteoporosis at high risk for fracture.

Disclosures: The study was funded by Radius Health, Inc. S Greenspan and C Deal participated in the advisory board for/received research funding from pharmaceutical companies including Amgen and Radius Health, Inc. L Fitzpatrick, B Mitlak, and Y Wang are employees of and own company stock in Radius Health, Inc. N Harvey and M McClung received consultancy fees and honoraria from pharmaceutical companies including Amgen and Radius Health, Inc. F Cosman was a consultant, advisor, and speaker for Amgen and Radius Health, Inc.